Healthtech Innovation Days HTID® will bring together more than 800 participants, including approximately 150 innovative European healthcare companies from more than 20 countries, above 300 international investors and 15 pharmaceutical and industrial companies, as well as international experts, patients and patient associations. Assobiotec is one of the European partner of the initiative.
The 2022 edition will be the opportunity to highlight the importance of a global approach that includes worldwide technological advances to build tomorrow's healthcare for all European citizens. Within this framework, experts will present, through a series of round tables, concrete ways to support the growth of European healthcare companies and will discuss new scientific and medical opportunities:
• “Translational microbiome medicine to treat serious oncology and infectious diseases”. Session that will address the issue of the microbiome as a treatment for infectious diseases and cancer. This round table will take place on Thursday, October 13 from 5:15 to 6:15 pm: https://htfc-eu.com/htid4-agenda/
• “Impact of mRNA application in innovative drugs with the support of adapted manufacturing settings”. This session, in memory of the biologist François Gros, will be moderated by Philippe Kourilsky, Professor Emeritus at the Collège de France. This round table will take place on Friday, October 14 from 11:00 to 11:55 am: https://htfc-eu.com/htid4-agenda/
• “Closing the gap in Women's Health: we need to be the change”. The roundtable will highlight the issues raised by women's healthcare. This roundtable will take place on Friday, October 14 from 1:00 to 1:55 pm: https://htfc-eu.com/htid4-agenda/
Other highlights will bring together international experts on central themes such as the In Vitro Diagnostics industry, the uses of AI in healthcare, the importance of human capital, the major involvement of patients and associations in the development of new approaches to care, and finally the added value of mastering clinical data processing.
This fourth edition of HTID® also marks the launch of the first pitch competition for European healthcare companies committed to patients. The objective is to offer these companies the opportunity to present their solutions to healthcare experts and investors. The winner will be awarded the "HealthTech For Care Innovation Award", which will provide them with privileged connections with HTFC's sponsors, visibility through dedicated communication and free access to the 5th edition of the HealthTech Innovation Days (HTID®) event. Two Italian companies will participate to che pitch competition: Neomatrix Biotech and Transactiva.
Among the investors: Adjuvant Capital, Abingworth, Cathay Capital, EIR Ventures, European Investment Bank, Eurazeo, Forbion, Fund+, HBM Partners, iBionext, Jeito, Karista, KKR, Lauxera Capital Partners, MAVIE Technologies, Panakes Partners, Sofinnova Partners, Turenne Capital, TVM Capital lifesciences will actively join the event.